**Figure 2.** In mild cases of RLS, dopamine agonist therapy can be continued after augmentation by dividing or advancing the dose before symptom onset while ensuring that the maxi-

الوصف

In mild RLS cases, dopamine agonist therapy management after augmentation is illustrated, showing dose adjustment strategies and transition to alternative medications including alpha-2-delta ligands and opioids for resistant cases.

More Figures from This Paper

$Treatment algorithm for restless legs syndrome outlines the step-wise pharmacologic approach from initial dopamine agonist therapy through iron supplementation and alternative agents for refractory or augmentation cases.$

Figure 1

Treatment algorithm for restless legs syndrome outlines the step-wise pharmacologic approach from initial dopamine agonist therapy through iron supplementation and alternative agents for refractory or augmentation cases.

flowchart

Figure 2

Diagram

1019 × 572px · 79,3 ك.ب

Source Paper

Pharmacologic Treatment of Restless Legs Syndrome.

Current neuropharmacology (2021)

PMID: 33380302

DOI: 10.2174/1570159X19666201230150127

Cite This Figure

![Figure 2: In mild RLS cases, dopamine agonist therapy management after augmentation is illustrated, showing dose adjustment strategies and transition to alternative medications including alpha-2-delta ligands and opioids for resistant cases.](https://pdfs.citedhealth.com/figures/33380302/201.png)

> Source: Qing Lv et al. "Pharmacologic Treatment of Restless Legs Syndrome.." *Current neuropharmacology*, 2021. PMID: [33380302](https://pubmed.ncbi.nlm.nih.gov/33380302/)

<figure>
  <img src="https://pdfs.citedhealth.com/figures/33380302/201.png" alt="In mild RLS cases, dopamine agonist therapy management after augmentation is illustrated, showing dose adjustment strategies and transition to alternative medications including alpha-2-delta ligands and opioids for resistant cases." />
  <figcaption>Figure 2. In mild RLS cases, dopamine agonist therapy management after augmentation is illustrated, showing dose adjustment strategies and transition to alternative medications including alpha-2-delta ligands and opioids for resistant cases.<br>  Source: Qing Lv et al. "Pharmacologic Treatment of Restless Legs Syndrome.." <em>Current neuropharmacology</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33380302/">33380302</a></figcaption>
</figure>

أدلة ذات صلة

الحديد لـ متلازمة تململ الساقين

التقييم A · 173 دراسات